Rockwell MedicalFRA:RWM 30 Forward PE Ratio is 36.19 as of Jul. 05, 2026. GuruFocus rates FRA:RWM with a GF Score™ of 30/100 and a GF Value™ of €0.90 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 407 Drug Manufacturers companies, Rockwell Medical ranks better than 90.91% on this metric.
Rockwell Medical (FRA:RWM) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Rockwell Medical Forward PE Ratio Related Terms
Rockwell Medical Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Rockwell Medical's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rockwell Medical Forward PE Ratio Chart
Rockwell Medical Annual Data
Trend
2015-12
Forward PE Ratio
12.53
Rockwell Medical Quarterly Data
2015-12
2016-03
2016-06
2024-09
Forward PE Ratio
12.53
192.31
312.50
53.19
FRA:RWM vs CPHI, TXMD, MRMD: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rockwell Medical Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Rockwell Medical's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Rockwell Medical (FRA:RWM) has a Forward PE Ratio of 36.19 as of Jul. 05, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Rockwell Medical and its competitors. According to the industry distribution chart, Rockwell Medical ranks #37 out of 407 companies in the Drug Manufacturers industry, placing it in the top 9.1%.
Is Rockwell Medical's Forward PE Ratio too high?
Rockwell Medical's current Forward PE Ratio is 36.19. The Drug Manufacturers industry median Forward PE Ratio is 17.47. Rockwell Medical's value of 36.19 is 107.2% above this industry median. Based on the distribution chart, Rockwell Medical ranks #37 out of 407 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Rockwell Medical has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rockwell Medical's Forward PE Ratio compare to CPHI and TXMD?
According to the Drug Manufacturers industry distribution chart, Rockwell Medical ranks #37 out of 407 companies for Forward PE Ratio. This places Rockwell Medical in the top 9% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 17.47. Rockwell Medical's value of 36.19 is 107.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.47, based on 407 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rockwell Medical's current Forward PE Ratio of 36.19 is 107.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Rockwell Medical and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rockwell Medical's current Forward PE Ratio is 36.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rockwell Medical stock overvalued right now?
Based on GuruFocus' analysis, Rockwell Medical (FRA:RWM) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.90, compared to a current price of €5.25 — trading 483.3% above its estimated fair value. The current Forward PE Ratio is 36.19 and 107.2% above the Drug Manufacturers industry median of 17.47. Rockwell Medical's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Rockwell Medical (FRA:RWM), the current Forward PE Ratio is 36.19 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rockwell Medical (FRA:RWM) Overvalued in 2026?
Based on GuruFocus' analysis, Rockwell Medical stock appears to be overvalued.
The current stock price of €5.25 is trading 483.3% above its estimated GF Value™ of €0.90.
GuruFocus considers Rockwell Medical to be Significantly Overvalued.
Key valuation signals for FRA:RWM:
Forward PE Ratio: 36.19
GF Value™: €0.90 vs. price of €5.25 (483.3% above fair value)
Industry Position: 107.2% above the Drug Manufacturers median (#37 of 407)
No single metric tells the full story. See the FRA:RWM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
30GF Score
Get the complete analysis for FRA:RWM
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RWM has been successfully added to your 